Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

Abstract : The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 Injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher in the dupilumab groups than in the placebo groups in pivotal studies.1,2 A recent study by Zhu et al3 reported new regional dermatoses in 17 patients with AD treated with dupilumab, with facial area involvement in 14 cases, whereas Blauvelt et al4 reported an equal improvement of AD with dupilumab on different anatomic regions in a post hoc analysis of data extracted from 4 phase 3 clinical trials.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02563178
Contributeur : Cécile Nowak <>
Soumis le : mardi 5 mai 2020 - 10:33:09
Dernière modification le : mercredi 27 mai 2020 - 04:02:00

Lien texte intégral

Identifiants

Collections

Citation

Angèle Soria, Aurélie Du-Thanh, Julien Seneschal, Marie Jachiet, Delphine Staumont-Sallé, et al.. Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab. JAMA Dermatology, American Medical Association, 2019, 155 (11), pp.1312. ⟨10.1001/jamadermatol.2019.2613⟩. ⟨hal-02563178⟩

Partager

Métriques

Consultations de la notice

15